Kolkata & New Delhi, India - Jun 05, 2007

TCG Lifesciences enters into a research collaboration with Forest Laboratories

TCG Lifesciences today announced a strategic collaboration with Forest Laboratories Holdings, Ltd., a wholly owned subsidiary of Forest Laboratories, Inc. (NYSE: FRX) to discover small molecule drug candidates for inflammatory diseases. Working closely with Forest scientists, Chembiotek, the chemistry and biology arm of TCG Lifesciences will carry out discovery research to identify and optimize lead molecules. The program will focus on an integrated approach involving chemistry, biology, ADME and animal pharmacology capabilities of Chembiotek. Forest will have full ownership of the compounds developed under the collaboration with unencumbered worldwide rights, and will fund all subsequent drug development and commercialization activities. Forest will pay Chembiotek undisclosed discovery milestones.

Commenting on the collaboration with Chembiotek, Dr. Ivan Gergel, Senior Vice President of Scientific Affairs, Forest Laboratories Inc. and President of the Forest Research Institute said, “We are pleased to commence this discovery research collaboration with Chembiotek. This collaboration is a part of our continued commitment to fill our early stage pipeline through discovery partnerships. We believe that, Chembiotek has the commitment throughout its organisation and the quality of personnel necessary for the success of this program.”

According to Mr. Swapan Bhattacharya, Managing Director, TCG Lifesciences, “This partnership with Forest is a culmination of the skills, capabilities and scale of operations we have developed over the past few years at TCG Lifesciences and more specifically at Chembiotek. In addition to our strong chemistry capabilities, we have developed the best biology and computational skills among CROs in India. Our talented and dedicated team of scientists have made this possible. This transaction represents the fourth integrated discovery project we have signed this year. ”

About TCG Lifesciences

TCG Lifesciences is a leading life sciences research and informatics services organisation that enables translational medicine approaches to discovery and development of superior drugs and biologics. TCG Lifesciences offers a new paradigm where focused research and development is seamlessly transitioned from bench to bedside, with laboratory data easily accessed and managed for critical decision making from one enterprise solution across the product development lifecycle.

• Chembiotek is one of the leaders in biology, chemistry, and pre-clinical research services
• Clininvent is uniquely positioned for genomics, proteomics and biomarker research in India, and is already one of the leaders in bio-banking and clinical development services
• LabVantage is the leading provider of thin-client enterprise laboratory informatics solutions

TCG Lifesciences is headquartered in Kolkata, India and has operations in Delhi, Mumbai, and Pune as well as in the United States and the United Kingdom.

For further information, please contact:
Rohit Sharan
Rediffusion DYR PR
098 18 200 359
rohit_sharan@ind.dyr.com